Fielmann Group (FLMNF) Fair Value & Analysis
Healthcare · US · Market cap $4.3B
Fair value as of: Jun 24, 2026
Analysis
Fielmann Group (FLMNF) currently trades at $50.75, while our model-based Fair Value estimate is $60.61 — implying the stock looks roughly 19.4% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Fielmann Group AG engages in vision care and audiology business in Germany, Switzerland, Austria, Spain, North America, and internationally. The company manufactures and sells visual aids mainly glasses, eyewear frames and lenses, sunglasses, contact lenses, ready-made reading glasses, hearing systems and its accessories, as well as personal protective equipment. It also offers its products under the fielmann, Optika Clarus, Optica & Audiologia Universitaria, Medical optica audicion, Shopko Optical, and SVS VISION brand names. The company sells its products through digital sales, retail stores, as well as Befitting, an optical e-commerce platform. The company was formerly known as Fielmann Aktiengesellschaft and changed its name to Fielmann Group AG in July 2023. Fielmann Group AG was founded in 1972 and is headquartered in Hamburg, Germany. Fielmann Group AG operates as a subsidiary of Korva SE.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Fielmann Group (FLMNF) undervalued?
What is the fair value of FLMNF?
What is the quality score of FLMNF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.